Theoretical framework for retrospective studies of the effectiveness of SARS-CoV-2 vaccines
Observational studies of the effectiveness of vaccines to prevent COVID-19 are needed to
inform real-world use. Such studies are now underway amid the ongoing rollout of SARS …
inform real-world use. Such studies are now underway amid the ongoing rollout of SARS …
TLR-based immune adjuvants
F Steinhagen, T Kinjo, C Bode, DM Klinman - Vaccine, 2011 - Elsevier
This work describes the nature and strength of the immune response induced by various Toll-
like receptor ligands and their ability to act as vaccine adjuvants. It reviews the various …
like receptor ligands and their ability to act as vaccine adjuvants. It reviews the various …
[HTML][HTML] Safety and efficacy of a monoclonal antibody against malaria in Mali
K Kayentao, A Ongoiba, AC Preston… - … England Journal of …, 2022 - Mass Medical Soc
Background CIS43LS is a monoclonal antibody that was shown to protect against controlled
Plasmodium falciparum infection in a phase 1 clinical trial. Whether a monoclonal antibody …
Plasmodium falciparum infection in a phase 1 clinical trial. Whether a monoclonal antibody …
[图书][B] World malaria report 2023
World Health Organization - 2023 - books.google.com
Page 1 World malaria וייוייו report 2023 wwwwww World Health Organization Page 2 World
malaria report 2023 ISBN 978-92-4-008617-3 (electronic version) ISBN 978-92-4-008618-0 …
malaria report 2023 ISBN 978-92-4-008617-3 (electronic version) ISBN 978-92-4-008618-0 …
Genetic diversity and protective efficacy of the RTS, S/AS01 malaria vaccine
DE Neafsey, M Juraska, T Bedford… - … England Journal of …, 2015 - Mass Medical Soc
Background The RTS, S/AS01 vaccine targets the circumsporozoite protein of Plasmodium
falciparum and has partial protective efficacy against clinical and severe malaria disease in …
falciparum and has partial protective efficacy against clinical and severe malaria disease in …
Immunogenicity of the RTS, S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised …
Summary Background The RTS, S/AS01 malaria vaccine targets the circumsporozoite
protein, inducing antibodies associated with the prevention of Plasmodium falciparum …
protein, inducing antibodies associated with the prevention of Plasmodium falciparum …
Systems analysis of protective immune responses to RTS, S malaria vaccination in humans
RTS, S is an advanced malaria vaccine candidate and confers significant protection against
Plasmodium falciparum infection in humans. Little is known about the molecular …
Plasmodium falciparum infection in humans. Little is known about the molecular …
[HTML][HTML] First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children
RTS, S Clinical Trials Partnership - New England Journal of …, 2011 - Mass Medical Soc
Background An ongoing phase 3 study of the efficacy, safety, and immunogenicity of
candidate malaria vaccine RTS, S/AS01 is being conducted in seven African countries …
candidate malaria vaccine RTS, S/AS01 is being conducted in seven African countries …
Reducing Plasmodium falciparum Malaria Transmission in Africa: A Model-Based Evaluation of Intervention Strategies
JT Griffin, TD Hollingsworth, LC Okell… - PLoS …, 2010 - journals.plos.org
Background Over the past decade malaria intervention coverage has been scaled up across
Africa. However, it remains unclear what overall reduction in transmission is achievable …
Africa. However, it remains unclear what overall reduction in transmission is achievable …
Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice
KL Mallory, JA Taylor, X Zou, IN Waghela… - npj Vaccines, 2021 - nature.com
Human malaria affects the vast majority of the world's population with the Plasmodium
falciparum species causing the highest rates of morbidity and mortality. With no licensed …
falciparum species causing the highest rates of morbidity and mortality. With no licensed …